Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
It was all about the pipeline during Eli Lilly’s fourth quarter earnings call, as company execs strove to convince analysts they’ve made progress in efforts to counter revenue losses from big-ticket products about to lose patent protection.